Skip to main content

John R. T. Monson, MD

John R. T. Monson, MD

Executive Medical Director Digestive Health and Surgery Institute

Cancer, Digestive Health and Surgery

John Monson

Overview

Dr. Monson is a board-certified colon and rectal surgeon with advanced fellowship training in surgical oncology, vascular surgery and colon and rectal surgery. His areas of expertise include the use of minimally invasive technologies in colorectal cancer treatment, including transanal endoscopic microsurgery (TEMS), laparoscopy and robotic surgery. In addition to his role as a leading physician with the AdventHealth Medical Group's elite colorectal surgery team, he also serves as Executive Director for Colorectal Surgery at AdventHealth in Orlando. Dr. Monson is credited with leading the development of laparoscopic colorectal surgery in the United Kingdom, and he is a former Chair of the U.K.'s National Training Program. His research encompasses a broad range of cancer-related areas including the development of national standards and qualitative assessments of decision-making in cancer care.

Awards & Recognition
He was the secretary to the Irish Higher Surgical Training Group, representing trainees on the National Council. His final year project won the Dr. Pamela Gilligan Prize in Sept 2016. Since coming to Florida, he has involved himself with myriad projects including being on the steering committee for AdventHealth to achieve National Accreditation for Rectal Cancer. He has authored over 35 original published papers, 4 books and 5 book chapters.

Articles

A Snapshot of the International Views of the Treatment of Rectal Cancer Patients, a Multi-regional Survey: International Tendencies in Rectal Cancer

WORLD JOURNAL OF SURGERY

2020

Selection and Outcomes in Abdominoperineal Resection

FRONTIERS IN ONCOLOGY

2020

TAMIS excision of Rectal GIST following effective treatment with neoadjuvant Imatinib - a video vignette

COLORECTAL DISEASE

2020

Defining the learning curve for transanal total mesorectal excision for rectal adenocarcinoma

SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES

2020

Allogeneic Leukocyte-Reduced Red Blood Cell Transfusion Is Associated with Postoperative Infectious Complications and Cancer Recurrence after Colon Cancer Resection

DIGESTIVE SURGERY

2020

Achieving Opioid-Free Major Colorectal Surgery: Is It Possible?

DIGESTIVE SURGERY

2020

Disease-free Survival and Local Recurrence for Laparoscopic Resection Compared With Open Resection of Stage II to III Rectal Cancer Follow-up Results of the ACOSOG Z6051 Randomized Controlled Trial

ANNALS OF SURGERY

2019

SSAT State-of-the-Art Conference: Advances in the Management of Rectal Cancer

JOURNAL OF GASTROINTESTINAL SURGERY

2019

Minimally invasive surgery for stage III colon adenocarcinoma is associated with less delay to initiation of adjuvant systemic therapy and improved survival

SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES

2019

Population-based study of outcomes following an initial acute diverticular abscess

BRITISH JOURNAL OF SURGERY

2019

Education & Training

Education

Trinity College School of Medicine Dublin Ireland

Residency

Royal College of Surgeons & St. James University Leeds UK

Fellowship

Royal College of Surgeons in Ireland, Dublin, Ireland; Surgical Oncology, Mayo Clinic, Rochester, MN

Specialty

Colon and Rectal Surgery

Board Certifications

American Board of Colon and Rectal Surgery

Associated Clinical Trials

NCT03827655

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of 2 Dose Regimens of Intravenous TAK-954 for the Prophylaxis and Treatment of Postoperative Gastrointestinal Dysfunction in Patients Undergoing Large- and Small-Bowel Resection

Icon for trial | TAK-954-2004 A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of 2 Dose Regimens of Intravenous TAK-954 for the Prophylaxis and Treatment of Postoperative Gastrointestinal Dysfunction in Patien

This study is currently enrolling.

The main purpose of this study is to understand if intravenous (IV) TAK-954 can improve post-surgery bowel function in patients who have had part of their bowel removed, and to determine the dose which is most safe and effectiv ...